- $358.21bn
- $405.02bn
- $65.01bn
Halozyme wins court order to block Merck's injected Keytruda in select European markets
Halozyme climbs on Dutch court win against Merck's injected Keytruda
Brief: Halozyme Wins Injunction Stopping Manufacture And Sale Of Merck's Keytruda SC In Multiple European Markets
Brief: Tempus Announces Multi-Year Collaboration With Moderna And Merck
Vaxcyte edges lower after $1 bln raise to fund pneumococcal vaccine
Focus: AI companies run virtual drug trials, aim to improve success of human studies
Vaxcyte down after starting $1 bln stock, convertible offerings
Factbox: Global healthcare companies invest billions to boost US presence
Spyre Therapeutics slips on $350 mln share sale
S&P 500 top and bottom performing stocks at about 03:30 p.m. EDT
Vaxcyte shares surge as pneumococcal vaccine succeeds in late-stage trial (updated)
Vaxcyte shares surge as pneumococcal vaccine meets main trial goals
Vaxcyte surges on pneumococcal vaccine late-stage trial success
US RESEARCH ROUNDUP-Danaher Corporation, Illumina, Reliance
Factbox: Major drugmakers turn to China for licensing deals
Spyre gains after Merck's drug succeeds in skin disease trial
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Merck's experimental skin disease drug succeeds in mid-stage study (updated)
Merck says experimental skin disease drug meets main goal in mid-stage study